Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen

View Full Paper
Ask AI
Bookmark
Share

Authors

SBStéphanie BoisclairKCKelli ColeFMFarzaneh Mashayekhi

Discussion

Loading...

Member takes

Overview

Phase I-IIb trial shows effective GvHD prophylaxis using abatacept in patients with hematologic malignancies, suggesting improved outcomes.

Key Points

  • Interim results indicate significant efficacy of an abatacept-based GvHD prevention regimen.
  • 54 patients enrolled with median follow-up of 8.7 months demonstrate low GvHD incidence and treatment-related mortality.
  • The regimen utilizes Thymoglobulin for immune reconstitution and optimal conditioning before transplant.
  • Longer follow-up is required to determine chronic GvHD risks linked to reduced posttransplant cyclophosphamide doses.

Cite This Study

Boisclair et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1a1https://doi.org/10.1182/blood-2025-2469
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  2. 2Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation2025
  3. 3Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  4. 4Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  5. 5Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025